Company Spotlight: Us2.ai Us2.ca - AI Detection for Cardiac Amyloidosis

NOV 19, 202612 MIN

Description

We unpack the FDA 510(k) summary for Us2.ca, an AI software device by Us2.ai designed to detect cardiac amyloidosis from echocardiograms. We break down the clinical testing data, demographic performance differences, and key limitations hospital buyers need to know. Key points Us2.ca is cleared via the FDA 510(k) pathway as substantially equivalent to the predicate device, EchoGo Cardiac Amyloidosis 1.0. The software is indicated for adult patients with a specific left ventricular wall thickness of ≥ 12mm. In retrospective testing of 1,647 patients, the device produced a confident prediction for 1434 patients, yielding an 87.1% success rate. Performance on the confident predictions showed an overall sensitivity of 86.9% and specificity of 87.4%. The summary outlines strict limitations: it does not provide a diagnosis, does not highlight regions of interest on the image, and was only externally validated on GE and Philips ultrasound systems. Source: FDA 510(k) summary K250151: Us2.ca (Eko.Ai Pte) - U.S. Food and Drug Administration, 2025 This episode is an AI-generated conversation summarising a public document; the hosts' voices are synthetic. It is for information only and is not medical advice. Always refer to the original source. Company: Eko.Ai Pte · Product: Us2.ca · FDA 510(k) K250151 Full transcript: https://ai-in-medicine-podcast.vercel.app/episodes/company-spotlight-us2-ai-us2-ca-ai-detection-for-cardiac-amyloidosis-67a2d8